These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 18342102)
1. [Cutaneous side effects of sorafenib and sunitinib]. Autier J; Mateus C; Wechsler J; Spatz A; Robert C Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102 [No Abstract] [Full Text] [Related]
2. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341 [No Abstract] [Full Text] [Related]
3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553 [TBL] [Abstract][Full Text] [Related]
4. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. Wollenberg A; Staehler M; Eames T Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979 [TBL] [Abstract][Full Text] [Related]
5. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. McLellan B; Kerr H Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797 [TBL] [Abstract][Full Text] [Related]
6. Risk of arterial thrombosis not increased by sorafenib or sunitinib. Minor DR J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133 [No Abstract] [Full Text] [Related]
7. Chemotherapeutic agents and the skin: An update. Heidary N; Naik H; Burgin S J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708 [TBL] [Abstract][Full Text] [Related]
8. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201 [No Abstract] [Full Text] [Related]
9. [Cutaneous side effects of antiangiogenic agents]. Robert C Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013 [TBL] [Abstract][Full Text] [Related]
10. [Dermatologic side effects induced by new angiogenesis inhibitors]. Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771 [TBL] [Abstract][Full Text] [Related]
11. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma]. Kondo T Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835 [No Abstract] [Full Text] [Related]
12. Reversible cardiomyopathy associated with sunitinib and sorafenib. Uraizee I; Cheng S; Moslehi J N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001 [No Abstract] [Full Text] [Related]
13. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001 [No Abstract] [Full Text] [Related]
14. [Hand-foot syndrome after administration of tyrosinkinase inhibitors]. Bednaríková D; Kocák I Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680 [TBL] [Abstract][Full Text] [Related]
15. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698 [TBL] [Abstract][Full Text] [Related]
17. Risk of bleeding not increased by sorafenib or sunitinib. Minor DR Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763 [No Abstract] [Full Text] [Related]
18. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905 [TBL] [Abstract][Full Text] [Related]
19. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549 [No Abstract] [Full Text] [Related]
20. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Porta C; Paglino C; Imarisio I; Bonomi L Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]